Search results
Results From The WOW.Com Content Network
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.
Thrombosis (from Ancient Greek θρόμβωσις (thrómbōsis) ' clotting ') is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.
Glanzmann's thrombasthenia can be inherited in an autosomal recessive manner [3] [4] or acquired as an autoimmune disorder. [3] [5]The bleeding tendency in Glanzmann's thrombasthenia is variable, [3] some individuals having minimal bruising, while others have frequent, severe, potentially fatal hemorrhages.
Erythrocyte aggregation is a physiological phenomenon that takes places in normal blood under low-flow conditions or at stasis. The presence or increased concentrations of acute phase proteins, particularly fibrinogen, results in enhanced erythrocyte aggregation.
In hematology, thrombocytopenia is a condition characterized by abnormally low levels of platelets (also known as thrombocytes) in the blood. [2] Low levels of platelets in turn may lead to prolonged or excessive bleeding.
The term thrombocyte (clot cell) came into use in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets (e.g. thrombocytopenia meaning low platelets).
Misfolded proteins can form protein aggregates or amyloid fibrils, get degraded, or refold back to its native structure.. In molecular biology, protein aggregation is a phenomenon in which intrinsically-disordered or mis-folded proteins aggregate (i.e., accumulate and clump together) either intra- or extracellularly.
The United States Geological Survey explains that, “when data are well documented, you know how and where to look for information and the results you return will be what you expect.” [2] The source information for data aggregation may originate from public records and criminal databases.